Less Than 95% Adherence to Nonnucleoside Reverse‐Transcriptase Inhibitor Therapy Can Lead to Viral Suppression

This publication has 18 references indexed in Scilit:

• Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness
  AIDS, 2006
• Pharmacokinetics of Nelfinavir and Efavirenz in Antiretroviral-Naïve, Human Immunodeficiency Virus-Infected Subjects when Administered Alone or in Combination with Nucleoside Analog Reverse Transcriptase Inhibitors
  Antimicrobial Agents and Chemotherapy, 2005
• Predictors of HIV Drug‐Resistance Mutations in a Large Antiretroviral‐Naive Cohort Initiating Triple Antiretroviral Therapy
  The Journal of Infectious Diseases, 2005
• Similar Adherence Rates Favor Different Virologic Outcomes for Patients Treated with Nonnucleoside Analogues or Protease Inhibitors
  Clinical Infectious Diseases, 2005
• Adherence to Highly Active Antiretroviral Therapy in the Homeless Population in San Francisco: A Prospective Study
  Clinical Infectious Diseases, 2004
• Disparities in HIV treatment and physician attitudes about delaying protease inhibitors for nonadherent patients
  Journal of General Internal Medicine, 2004
• High levels of adherence do not prevent accumulation of HIV drug resistance mutations
  AIDS, 2003
• Is average adherence to HIV antiretroviral therapy enough?
  Journal of General Internal Medicine, 2002
• Impact of Adherence and Highly Active Antiretroviral Therapy on Survival in HIV-Infected Patients
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
• Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
  New England Journal of Medicine, 1999